AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.670

-1.090-6.50%

Volume:2.19M

Turnover:34.75M

Market Cap:5.31B

PE:117.83

High:16.610

Open:16.450

Low:15.500

Close:16.760

52wk High:18.320

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:1.67

T/O Rate:0.80%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.133

EPS(LYR):-0.029

ROE:7.36%

ROA:2.71%

PB:7.81

PE(LYR):-532.69

Loading ...

Overview Company News Filings

BRIEF-Telix Pharmaceuticals Launches Offering Of $550 MLN Convertible Notes Due 2031 To Be Issued By Its Unit

Telix launches US$550 million convertible notes offering due 2031

Telix Refinances Convertible Bonds

Telix Pharmaceuticals Ltd - Launches an Offering of US$550 Mln Convertible Notes Due 2031 to Be Issued by Its Wholly-Owned Subsidiary

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Initial Conversion Price Will Be at a Premium to Telix's Current Share Price.

THOMSON REUTERS

Regeneron Pharmaceuticals Inc - Telix Will Receive an Upfront Cash Payment of US$40 Mln From Regeneron

THOMSON REUTERS

BUZZ-Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope

Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Telix Pharmaceuticals Ltd - to Receive $40 Mln Upfront and up to $2.1 Bln in Milestones Plus Royalties

THOMSON REUTERS

Telix Pharmaceuticals Ltd-Telix and Regeneron Announce Radiopharma Collaboration

THOMSON REUTERS

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Amid Lingering Geopolitical Uncertainty, CPI Focus

MT Newswires Live

BUZZ-Australia's Telix Pharmaceuticals rises as US FDA approves drug application

Stock Track | Telix Pharmaceuticals Soars 8.14% Intraday on FDA Acceptance of Brain Cancer Imaging Agent NDA

Telix Pharmaceuticals Says US FDA Accepts New Drug Application for Brain Cancer Imaging Agent

MT Newswires Live

FDA Accepts Nda for Tlx101-Px (Pixclara®)

THOMSON REUTERS

FDA Accepts NDA for TLX101-Px (Pixclara®)

Telix says FDA accepts resubmitted Pixclara glioma PET imaging NDA

Telix Pharmaceuticals Ltd-FDA Accepts Nda for Tlx101-Px (Pixclara)

THOMSON REUTERS

Telix Pharmaceuticals Ltd - FY2026 Guidance Excludes Tlx101-Px Revenue Contribution

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/TLX.AU/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.67,"timestamp":1789107120000,"preClose":16.76,"halted":0,"volume":2193327,"delay":0,"changeRate":-0.06503579952267312,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.13298534576385085,"marketStatus":"Closed","change":-1.09,"latestTime":"09-11 16:12:00 AEST","open":16.45,"high":16.61,"low":15.5,"amount":34747785,"amplitude":0.066229,"askPrice":15.75,"askSize":635,"bidPrice":15.63,"bidSize":639,"shortable":3,"etf":0,"ttmEps":0.13298534576385085,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":16.76,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":1.667839,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":16.76,"auctionPrice":15.67,"auctionVolume":394284,"auctionTime":1789107003557,"referencePrice":15.67,"referenceTime":1789110091623,"auction":3,"marketStatus":"盘后竞价","timestamp":1789107003557}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029417,"volumeRatio":1.667839,"shares":338721355,"dividePrice":0,"high":16.61,"amplitude":0.066229,"preClose":16.76,"low":15.5,"week52Low":8.26,"pbRate":"7.81","psRate":"4.27","week52High":18.32,"institutionHeld":0,"latestPrice":15.67,"committee":0.00314,"eps":0.13298534576385085,"divideRate":0,"volume":2193327,"delay":0,"ttmEps":0.13298534576385085,"open":16.45,"prevYearClose":11.2,"prevWeekClose":16.47,"prevMonthClose":15.36,"prevQuarterClose":16.58,"fiveDayClose":16.47,"twentyDayClose":16.73,"sixtyDayClose":14.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627448835","title":"BRIEF-Telix Pharmaceuticals Launches Offering Of $550 MLN Convertible Notes Due 2031 To Be Issued By Its Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2627448835","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627448835?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:06","pubTimestamp":1776164800,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Launches Offering Of $550 MLN Convertible Notes Due 2031 To Be Issued By Its UnitApril 14  - Telix Pharmaceuticals Ltd TLX.AX:TELIX REFINANCES CONVERTIBLE BONDSLAUNCHES AN OFFERING OF US$550 MILLION CONVERTIBLE NOTES DUE 2031 TO BE ISSUED BY ITS WHOLLY-OWNED SUBSIDIARYINITIAL CONVERSION PRICE WILL BE AT A PREMIUM TO TELIX'S CURRENT SHARE PRICE.INTENDED THAT NET PROCEEDS TO BE USED TO REPURCHASE EXISTING CONVERTIBLE BONDS DUE 2029Further company coverage: TLX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40W102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627416477","title":"Telix launches US$550 million convertible notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2627416477","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627416477?lang=en_us&edition=fundamental","pubTime":"2026-04-14 16:36","pubTimestamp":1776155793,"startTime":"0","endTime":"0","summary":"Telix launched offering of US$ 550 million convertible notes due 2031.Net proceeds earmarked for repurchase of existing convertible bonds due 2029.Bookbuild set to determine final terms before market open April 15, 2026.Notes marketed with coupon or yield guidance of 1.5%-1.75%.Conversion premium guided at 35%-37.5% to reference share price set via concurrent delta placement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLn07nW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627416002","title":"Telix Refinances Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2627416002","media":"prnewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627416002?lang=en_us&edition=fundamental","pubTime":"2026-04-14 16:32","pubTimestamp":1776155520,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited   today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals  Inc. , and guaranteed by Telix and Telix Pharmaceuticals  Inc. . The convertible notes, also referred to as \"convertible bonds\" , are convertible into fully paid ordinary shares in Telix .Managing Director and Group CEO, Dr. Christian Behrenbruch, said: \"The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing.\". The new Convertible Bonds represent attractive, low-cost financing to Telix and are non-dilutive until any potential future conversions occur. The initial conversion price will be at a premium to Telix's current share price.After deduction of commissions, professional fees and other administrat","market":"nz","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-refinances-convertible-bonds-302741509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4543","BK4526","ASX.AU","BK4141","BK7039","TLX.AU","BK7067","ASX","SEC.AU","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627949068","title":"Telix Pharmaceuticals Ltd - Launches an Offering of US$550 Mln Convertible Notes Due 2031 to Be Issued by Its Wholly-Owned Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2627949068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627949068?lang=en_us&edition=fundamental","pubTime":"2026-04-14 14:54","pubTimestamp":1776149677,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40W102:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627490622","title":"Telix Pharmaceuticals Ltd - Initial Conversion Price Will Be at a Premium to Telix's Current Share Price.","url":"https://stock-news.laohu8.com/highlight/detail?id=2627490622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627490622?lang=en_us&edition=fundamental","pubTime":"2026-04-14 14:54","pubTimestamp":1776149677,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40W102:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627897434","title":"Regeneron Pharmaceuticals Inc - Telix Will Receive an Upfront Cash Payment of US$40 Mln From Regeneron","url":"https://stock-news.laohu8.com/highlight/detail?id=2627897434","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627897434?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:30","pubTimestamp":1776076200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUACB1KYL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU0053666078.USD","LU0109394709.USD","LU2362541513.USD","LU2089984988.USD","BK4588","BK7067","LU2362541273.HKD","BK4585","LU1974910355.USD","LU0882574055.USD","LU0114720955.EUR","BK4139","LU0289739699.SGD","LU1917777945.USD","LU2468319806.SGD","LU0823416689.USD","LU2362540622.SGD","LU2023250504.SGD","LU0320765992.SGD","LU0823434740.USD","LU2237438978.USD","LU0823434583.USD","LU0058720904.USD","REGN","LU2106854487.HKD","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627483320","title":"BUZZ-Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope","url":"https://stock-news.laohu8.com/highlight/detail?id=2627483320","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627483320?lang=en_us&edition=fundamental","pubTime":"2026-04-13 10:38","pubTimestamp":1776047920,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope** Telix Pharmaceuticals TLX.AX rises as much as 8.8% to A$15.93, highest since November 5, 2025** Stoc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL6N40W05T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU1974910355.USD","BK4585","LU2089984988.USD","LU0289739699.SGD","BK4588","LU2468319806.SGD","LU2362541513.USD","REGN","LU0823434583.USD","LU0053666078.USD","LU2237438978.USD","LU0058720904.USD","LU0823434740.USD","LU2362540622.SGD","LU0114720955.EUR","LU0882574055.USD","LU0320765992.SGD","LU0109394709.USD","LU2106854487.HKD","TLX.AU","BK7067","LU0889565916.HKD","LU1917777945.USD","LU2023250504.SGD","LU2362541273.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158547007","title":"Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1158547007","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158547007?lang=en_us&edition=fundamental","pubTime":"2026-04-13 08:04","pubTimestamp":1776038653,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD (TLX.AU) saw its stock price soar 7.58% during intraday trading on Monday, following a significant corporate announcement.The sharp increase is attributed to the company's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627101920","title":"Telix and Regeneron Announce Strategic Radiopharma Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2627101920","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627101920?lang=en_us&edition=fundamental","pubTime":"2026-04-13 06:57","pubTimestamp":1776034620,"startTime":"0","endTime":"0","summary":"Telix to receive US$40 million upfront for four initial programs with optionality on a per program basis to co-fund commercialization and profit-share or earnup to an aggregate of US$2.1 billion in developmentand commercial milestone payments pluslow double-digit royalties.","market":"sg","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-and-regeneron-announce-strategic-radiopharma-collaboration-302739967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434740.USD","BK7039","LU2237438978.USD","BK4543","LU0289739699.SGD","LU2362541273.HKD","TLX.AU","BK4526","LU2106854487.HKD","BK4139","ASX.AU","LU0053666078.USD","LU0320765992.SGD","TLX","LU2023250504.SGD","REGN","LU1917777945.USD","ASX","LU0882574055.USD","LU2089984988.USD","SEC.AU","BK4585","LU0114720955.EUR","BK4141","BK4588","LU0889565916.HKD","LU2362540622.SGD","LU0109394709.USD","LU2468319806.SGD","LU0058720904.USD","LU1974910355.USD","LU0823416689.USD","BK7067","LU0823434583.USD","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627888101","title":"Telix Pharmaceuticals Ltd - to Receive $40 Mln Upfront and up to $2.1 Bln in Milestones Plus Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2627888101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627888101?lang=en_us&edition=fundamental","pubTime":"2026-04-13 06:28","pubTimestamp":1776032882,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260412:nTUE9FVW25:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0058720904.USD","LU0114720955.EUR","LU2089984988.USD","TLX.AU","LU2362541273.HKD","LU0889565916.HKD","REGN","LU0109394709.USD","LU2023250504.SGD","LU2237438978.USD","LU2468319806.SGD","LU2362540622.SGD","LU0289739699.SGD","LU0053666078.USD","LU0823434583.USD","LU0823434740.USD","LU0823416689.USD","LU2106854487.HKD","BK4585","BK7067","LU2362541513.USD","LU1974910355.USD","BK4588","LU0882574055.USD","LU0320765992.SGD","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627710900","title":"Telix Pharmaceuticals Ltd-Telix and Regeneron Announce Radiopharma Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2627710900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627710900?lang=en_us&edition=fundamental","pubTime":"2026-04-13 06:28","pubTimestamp":1776032882,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260412:nTUE9FVW25:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118762","title":"Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Amid Lingering Geopolitical Uncertainty, CPI Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118762","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626118762?lang=en_us&edition=fundamental","pubTime":"2026-04-10 21:15","pubTimestamp":1775826917,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.1% higher in Friday's premarket activity amid lingering geopolitica","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IGM","BETH","XLE","SHAK","IYH","SPY","VDC","E","XLY","EETH","FDN","RTH","VIS","XLV","NMG.AU","TSM","VHT","QQQ","USO","UNG","SOXX","VHT.AU","TLX.AU","XSD","BITO","NMG","IYK","IYE","GLD","XLK","XLP","AOS","IBB","SLV","SPY.AU","IYJ","EQR","TLX","IYW","EXI","XLI","SLM","XRT","IVV","SLM.AU","RTH.AU","FAS","EEM","XLF","FAZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626151448","title":"BUZZ-Australia's Telix Pharmaceuticals rises as US FDA approves drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2626151448","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626151448?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:43","pubTimestamp":1775781831,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals rises as US FDA approves drug application** Telix Pharmaceuticals TLX.AX rises as much as 8.4% to A$14.79, highest since December 8** Co says U.S. FDA accepts resubmitted New Drug Application for TLX101-Px** TLX101-Px is an investigational Positron emission tomography agent for imaging of glioma ** YTD, TLX up 26.3%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL4N40T011:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194270889","title":"Stock Track | Telix Pharmaceuticals Soars 8.14% Intraday on FDA Acceptance of Brain Cancer Imaging Agent NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1194270889","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194270889?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:02","pubTimestamp":1775779363,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) saw its shares surge 8.14% during intraday trading on Friday, following a significant regulatory development for one of its key investigational...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626126156","title":"Telix Pharmaceuticals Says US FDA Accepts New Drug Application for Brain Cancer Imaging Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2626126156","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626126156?lang=en_us&edition=fundamental","pubTime":"2026-04-10 07:25","pubTimestamp":1775777139,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said the US Food and Drug Administration  has accepted its resubmitted new drug application for TLX101-Px, an investigational positron emission tomography  agent for the imaging of glioma, a form of brain cancer, according to a Friday filing with the Australian bourse.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK7047","TLX.AU","TLX","PET.AU","BK4585","BK7067","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626815689","title":"FDA Accepts Nda for Tlx101-Px (Pixclara®)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626815689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626815689?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:51","pubTimestamp":1775775089,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUARRPF8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626156814","title":"FDA Accepts NDA for TLX101-Px (Pixclara®)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626156814","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626156814?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:50","pubTimestamp":1775775000,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces that the United States  Food and Drug Administration  has accepted the Company's resubmitted New Drug Application  for TLX101-Px[1], , an investigational PET[3] agent for the imaging of glioma , and has assigned a PDUFA[4] goal date of September 11, 2026.The approval of TLX101-Px will fulfil a significant unmet medical need for the characterization of recurrent or progressive glioma from treatment related changes in both adult and pediatric patients[5]. Neuroimaging of glioma with 18F-FET is already broadly recommended in international clinical practice guidelines – including NCCN Guidelines[6] – and TLX101-Px has been granted Orphan Drug[7] and Fast Track[8] designations by the FDA.Patrick Wen, MD, E. Antonio Chiocca,MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added, \"Distinguishing tumor progression from treatment-related c","market":"sh","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fda-accepts-nda-for-tlx101-px-pixclara-302738824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7039","LABU","SEC.AU","ASX","BK4588","BK7067","ASX.AU","BK4526","CNS","BK4141","BK4543","BK4585","BK7104","TLX","BK4139","GBM.AU","TLX.AU","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215526","title":"Telix says FDA accepts resubmitted Pixclara glioma PET imaging NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215526","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626215526?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:37","pubTimestamp":1775774227,"startTime":"0","endTime":"0","summary":"FDA accepted Telix resubmitted NDA for TLX101-Px , an investigational PET imaging agent for glioma.Telix noted no Pixclara revenue included in FY 2026 guidance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on April 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLbwm1Py:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626155157","title":"Telix Pharmaceuticals Ltd-FDA Accepts Nda for Tlx101-Px (Pixclara)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626155157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626155157?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:26","pubTimestamp":1775773584,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUEPBZWJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626150155","title":"Telix Pharmaceuticals Ltd - FY2026 Guidance Excludes Tlx101-Px Revenue Contribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2626150155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626150155?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:26","pubTimestamp":1775773584,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUEPBZWJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":198,"code":"91000000","status":"200"}]}}